Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals Stock
Heavy losses for Biocryst Pharmaceuticals today as the stock fell by -€0.294 (-3.530%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Biocryst Pharmaceuticals.
Based on the current price of 8.01 € the target price of 17 € shows a potential of 112.23% for Biocryst Pharmaceuticals which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biocryst Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | -3.530% | -2.886% | -8.436% | 11.219% | 22.178% | 15.053% | -41.016% |
| Evolus Inc | -0.040% | -0.496% | -14.130% | -33.154% | -4.330% | -42.703% | -41.085% |
| Heron Therapeutics Inc. | -1.990% | 2.964% | 15.558% | -71.508% | -61.329% | -69.229% | -95.846% |
| Rhythm Pharmaceuticals | -1.080% | 1.667% | -5.181% | 26.207% | -2.139% | 479.114% | 535.417% |
Comments
BioCryst Pharmaceuticals (BCRX) had its price target raised by Royal Bank Of Canada from $13.00 to $14.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals (BCRX) had its price target raised by Cantor Fitzgerald from $27.00 to $29.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for BCRX provided by MarketBeat